SC-ADTRAN-HOLDINGS,-INC.
15.5.2024 14:01:32 CEST | Business Wire | Press release
Adtran today announced that TruVista is harnessing its ALM fiber monitoring solution to ensure the reliability of its high-speed broadband services. Adtran’s ALM gives TruVista’s maintenance teams comprehensive and immediate insight into their optical infrastructure, including third-party links. By continuously probing the fiber network for breaks, bends, damage and more, the technology empowers field forces to take swift, targeted action to resolve any issues. This proactive approach enables TruVista to deliver ultra-reliable high-speed connectivity even more efficiently, ensuring its subscribers benefit from robust, sustainable and secure services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515244858/en/
Adtran’s ALM is providing TruVista with real-time data on its fiber network, enabling rapid response to any issues. (Photo: Business Wire)
“At TruVista, enhancing the subscriber experience is our top priority. That’s why we chose to elevate our services by leveraging Adtran’s comprehensive fiber assurance platform,” said Sam Fitzgerald, VP of technology at TruVista. “We have a lot of fiber spread across a huge expanse of land. Given this scale, we need the best possible protection against unpredictable events like storm damage or accidental cuts. Real-time, in-service monitoring of our network is critical to promptly identify and address any anomalies. ALM enables us to detect the slightest issues as soon as they occur, giving our network an essential layer of protection. It ensures that our subscribers consistently receive the best possible broadband experience.”
TruVista is utilizing Adtran’s ALM technology to enhance service delivery for its residential and business subscribers across South Carolina and Georgia. Engineered for power efficiency, ALM protects the company’s investment and ensures consistent service quality. It works seamlessly with any optical transmission technology, enabling swift fiber fault detection irrespective of the network equipment used. The system monitors the network in real-time and provides precise alerts for faults, irregularities or security breaches. With access to detailed performance data, TruVista is reducing the need for truck rolls and cutting operational costs, helping to streamline network management and bolstering service reliability.
“Over the last ten years, we’ve helped TruVista build a network spanning two states, enabling tens of thousands of subscribers to play, stream, learn and work from home. Now, by deploying our ALM, they join a growing list of forward-thinking service providers who are making their networks more robust, reliable and secure. With ALM surveilling TruVista’s fiber 24/7, the efficiency of their high-quality broadband services just got a major boost,” commented John Scherzinger, GM of Americas sales at Adtran. “What sets our ALM apart is its ease of use and open management interfaces. Simply drop it into your network and it instantly starts monitoring the physical integrity of any fiber link. It’s completely service-agnostic. This simplicity and versatility are what make it so appealing to service providers.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515244858/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom